Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biosource International -- Ignore unavailable to you. Want to Upgrade?

To: craig luplow who wrote (303)	10/29/1997 7:20:00 PM
From: Douglas V. Fant	Read Replies (1) \| Respond to of 696

craig, Heck! I wasn't paying attention, looking for the announcement! Let me go read it and get back to you on this Thread.... OK Craig- just checked Zack's-BIOI came in dead on its estimate of $.10/share for this quarter.... Sincerely, Doug F.

To: craig luplow who wrote (303)	10/29/1997 9:12:00 PM
From: Orwell	Respond to of 696

I am sure some may be disappointed at the slow sales growth, but one must consider this: 1) The steady sales indicate a consistent and loyal customer base, a base which can be used to sell a future expanded line of products. 2) Sales are only slightly up, but profit is not down. Thus the management is cognizant of the bottom line, and are keeping a good eye on expenses in order to maintain the profit necessary for shareholder value. 3) BIOI has a very small number of shares, and lots of room to grow when the time comes to issue a few more shares. 4) Combine this with the fact that the company has $14million in cash, and is profitable. This leads to the ability to fund expansion and/or takeover of other companies. There are alot of burgeoning companies in this field, and takeovers of private companies can often be done at lower multiples. BIOI is a safer bet than most for those interested in having some biotech diversity in their portfolio. O.